Abacavir acetate: Phase II started

Cellceutix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 50, 100 and 200 mg daily Prurisol in about 100 patients. The company is developing Prurisol under section 505(b)(2)...